Neurogenic Orthostatic Hypotension
Neurogenic orthostatic hypotension (nOH) is a sustained fall in blood pressure upon standing caused by failure of the sympathetic nervous system to adequately increase peripheral vascular resistance. Unlike non-neurogenic causes of orthostatic hypotension (dehydration, hemorrhage, medication effects), nOH reflects structural or functional impairment of autonomic pathways and is a hallmark feature of several neurodegenerative disorders, particularly the synucleinopathies. The management of nOH is uniquely challenging because its treatment frequently exacerbates coexisting supine hypertension, creating a therapeutic dilemma that requires careful balancing of risks. Recognition of nOH is critical because it is associated with increased fall risk, syncope-related injury, cardiovascular morbidity, cognitive impairment, and mortality.
Bottom Line
- Definition: Sustained SBP drop ≥20 mmHg or DBP drop ≥10 mmHg within 3 minutes of standing, caused by failure of autonomic sympathetic vasoconstriction
- Neurogenic vs non-neurogenic: Neurogenic OH shows absent compensatory heart rate rise (<10–15 bpm increase); non-neurogenic OH produces appropriate tachycardia
- Key etiologies: MSA (most severe), Parkinson disease (30–50%), dementia with Lewy bodies, pure autonomic failure, diabetic autonomic neuropathy, amyloid neuropathy
- The supine hypertension dilemma: Present in ~50% of nOH patients; treating OH worsens supine HTN and vice versa
- Treatment: Non-pharmacologic measures first (rise slowly, compression, fluid/salt, elevate head of bed); pharmacologic — midodrine (first-line), droxidopa (FDA-approved for nOH in synucleinopathies), fludrocortisone
- Coat-hanger pain: Suboccipital/posterior neck and shoulder pain on standing is characteristic of nOH and reflects ischemia of cervical paraspinal muscles
Pathophysiology
Normal hemodynamic regulation during standing requires an intact baroreflex arc: baroreceptors in the carotid sinus and aortic arch detect the gravity-mediated fall in blood pressure, afferent signals travel via the glossopharyngeal and vagus nerves to the brainstem (nucleus tractus solitarius), and efferent sympathetic signals increase heart rate, cardiac contractility, and peripheral vasoconstriction. In neurogenic OH, disruption at any point along this pathway — central (brainstem, spinal intermediolateral cell column) or peripheral (sympathetic ganglia, postganglionic neurons) — results in inadequate vasoconstrictive compensation.
| Feature | Neurogenic OH | Non-Neurogenic OH |
|---|---|---|
| Heart rate response to standing | Blunted (<10–15 bpm increase) — autonomic failure prevents compensatory tachycardia | Appropriate tachycardia (≥15–20 bpm increase) — intact autonomic reflexes attempting compensation |
| Mechanism | Failure of sympathetic efferent vasoconstriction due to neuronal degeneration or dysfunction | Reduced effective circulating volume (dehydration, hemorrhage) or pharmacologic vasodilation |
| Plasma norepinephrine | Low or fails to rise appropriately on standing (peripheral lesion) or normal supine with poor standing increment (central lesion) | Elevated and rises further on standing (appropriate sympathetic activation) |
| Valsalva maneuver | Absent late phase II BP recovery and absent phase IV overshoot | Normal Valsalva response |
| Common causes | MSA, PD, DLB, PAF, diabetic neuropathy, amyloid neuropathy, AAG, spinal cord injury | Dehydration, hemorrhage, medications (antihypertensives, diuretics), adrenal insufficiency, sepsis |
| Treatment approach | Volume expansion + vasopressors (midodrine, droxidopa) | Address underlying cause (fluid resuscitation, medication adjustment) |
Etiologies
Neurodegenerative Causes (Synucleinopathies)
| Condition | Prevalence of nOH | Mechanism | Clinical Context |
|---|---|---|---|
| Multiple System Atrophy (MSA) | >75% (often the most severe) | Central — degeneration of brainstem and intermediolateral cell column; preganglionic sympathetic loss | Cerebellar (MSA-C) or parkinsonian (MSA-P) features; early severe autonomic failure; rapid progression |
| Parkinson Disease | 30–50% | Peripheral — alpha-synuclein deposition in sympathetic ganglia and cardiac sympathetic nerves | Develops with disease progression; levodopa can worsen; cardiac MIBG reduced |
| Dementia with Lewy Bodies | 30–50% | Peripheral — similar to PD with postganglionic sympathetic denervation | Cognitive decline, visual hallucinations, parkinsonism, REM sleep behavior disorder |
| Pure Autonomic Failure | ~100% (defining feature) | Peripheral — selective degeneration of postganglionic sympathetic neurons | Isolated autonomic failure without motor/cerebellar/cognitive deficits; risk of phenoconversion |
Peripheral Neuropathic Causes
- Diabetic autonomic neuropathy: Most common peripheral cause of nOH; typically occurs in the setting of established diabetic polyneuropathy; associated with cardiovascular mortality
- Amyloid neuropathy: AL amyloidosis and hereditary transthyretin (hATTR) amyloidosis; severe autonomic failure with neuropathy, cardiomyopathy; tafamidis, patisiran, and inotersen for hATTR
- Autoimmune autonomic ganglionopathy: Ganglionic AChR antibodies; subacute onset pandysautonomia; may respond to immunotherapy
- Other neuropathies: Sjogren syndrome, sarcoidosis, paraneoplastic, HIV, Chagas disease
Other Causes
- Spinal cord injury: Disruption of descending sympathetic pathways; severity depends on level (lesions above T6 → loss of splanchnic vascular tone)
- Medications: Antihypertensives, dopaminergic agents (levodopa, dopamine agonists), diuretics, tricyclic antidepressants, alpha-blockers (tamsulosin for BPH), nitrates
- Adrenal insufficiency: Cortisol and aldosterone deficiency; associated hyponatremia and hyperkalemia
Clinical Features
Symptoms of nOH result from hypoperfusion of the brain and other organs upon assuming the upright position. Symptom severity often correlates with the magnitude of blood pressure drop, but there is substantial individual variation. Some patients with profound orthostatic hypotension may be relatively asymptomatic due to chronic adaptation, while others are highly symptomatic with modest drops.
- Lightheadedness and presyncope: The most common symptom; occurs within seconds to minutes of standing
- Syncope and falls: Major source of morbidity; can occur without warning (absent prodrome due to impaired autonomic reflexes)
- Visual dimming: Graying, tunneling, or complete loss of vision on standing — reflects retinal hypoperfusion
- Coat-hanger pain: Dull, aching pain in the suboccipital, posterior cervical, and shoulder regions on standing; pathognomonic for nOH; reflects ischemia of posterior cervical and trapezius muscles due to hypoperfusion; resolves on sitting or lying down
- Cognitive difficulty: Impaired concentration and executive function on standing; may mimic dementia in elderly patients
- Generalized weakness and fatigue: Particularly prominent in the morning and after meals
- Post-prandial worsening: Splanchnic blood pooling after meals reduces effective circulating volume, exacerbating OH
Dangerous Presentations Requiring Urgent Management
- Recurrent syncope with falls and injuries: High risk of fractures (hip, vertebral), subdural hematoma, and head trauma; may require hospitalization
- Severe post-prandial hypotension: SBP drops ≥30–40 mmHg after meals; can trigger ischemic events (stroke, MI)
- Severe supine hypertension: SBP >180–200 mmHg supine; end-organ damage risk (cerebrovascular, cardiac, renal)
- Acute worsening of nOH: Consider new medication, dehydration, infection, adrenal crisis, GI bleeding
The Supine Hypertension Dilemma
Supine hypertension is present in approximately 50% of patients with nOH and represents one of the most challenging management problems in autonomic medicine. The same autonomic failure that prevents vasoconstriction on standing also impairs vasodilation when supine, leading to elevated blood pressure in the recumbent position. This is further exacerbated by volume expansion and vasopressor medications used to treat OH.
Managing the OH–Supine HTN Paradox
- Elevate head of bed 10–15 degrees: Single most effective strategy; reduces nocturnal supine hypertension, nocturnal diuresis, and morning orthostatic hypotension
- Time vasopressor medications: Give midodrine no later than mid-afternoon; avoid fludrocortisone at bedtime
- Short-acting antihypertensives at bedtime:
- Nitroglycerin patch (0.1–0.2 mg/hr) — applied at bedtime, removed in the morning
- Losartan 25–50 mg at bedtime
- Hydralazine 25–50 mg at bedtime
- Sildenafil 25 mg at bedtime (vasodilatory effect)
- Monitor with 24-hour ambulatory BP: Quantifies the magnitude of both orthostatic drops and supine hypertension; guides treatment titration
- Avoid strict supine hypertension treatment targets: Attempting to normalize supine BP often worsens orthostatic symptoms; tolerate mild-moderate supine HTN if the patient is functionally improved
Diagnosis and Workup
Orthostatic Vital Signs (Bedside)
- Measure blood pressure and heart rate after ≥5 minutes supine, then at 1 minute and 3 minutes of standing
- Diagnostic criteria: SBP drop ≥20 mmHg or DBP drop ≥10 mmHg within 3 minutes of standing
- Neurogenic indicator: Heart rate increase <10–15 bpm on standing (absent compensatory tachycardia)
- Some experts use a ΔHR/ΔSBP ratio <0.5 bpm/mmHg as a marker for neurogenic cause
Autonomic Testing Battery
- Tilt table testing: Continuous beat-to-beat BP and HR monitoring; more sensitive than bedside orthostatics; can detect delayed OH
- Valsalva maneuver (beat-to-beat BP): Absent late phase II recovery and absent phase IV overshoot → adrenergic failure
- Heart rate variability: Reduced HR response to deep breathing → cardiovagal dysfunction
- QSART / thermoregulatory sweat test: Sudomotor testing to assess distribution and severity of autonomic denervation
Laboratory Evaluation
| Test | Purpose | Key Findings |
|---|---|---|
| Supine and standing plasma catecholamines | Localizes lesion (central vs peripheral) | Low supine NE (<100 pg/mL) + failure to rise = peripheral (PAF, PD); normal supine NE + failure to rise = central (MSA) |
| 24-hour ambulatory BP monitoring | Quantifies OH and supine HTN; assesses nocturnal dipping | Reverse dipping (BP rises at night) is typical of nOH with supine HTN |
| Cardiac MIBG scintigraphy | Postganglionic cardiac sympathetic innervation | Reduced uptake: PD, DLB, PAF; preserved: MSA |
| BMP, CBC, cortisol | Rule out non-neurogenic causes | Adrenal insufficiency, anemia, dehydration |
| Ganglionic AChR antibodies | Autoimmune autonomic ganglionopathy | Positive in AAG; titer correlates with severity |
| TTR gene testing, serum free light chains | Amyloid neuropathy | hATTR mutations; AL amyloidosis |
| Skin biopsy (IENFD) | Small fiber neuropathy | Reduced epidermal nerve fiber density |
Treatment
Non-Pharmacologic Measures
Non-pharmacologic strategies are foundational in nOH management and should be initiated in all patients. These interventions can raise standing SBP by 10–20 mmHg and are often sufficient for mild OH.
- Rise slowly: Sit at the edge of the bed for 1–2 minutes before standing; perform ankle dorsiflexion (calf pump) while seated
- Physical counter-maneuvers: Leg crossing and tensing, squatting, toe-raising, marching in place — increase venous return by 20–30%
- Compression garments: Abdominal binder (most effective, compresses splanchnic vascular bed) ± thigh-high compression stockings (30–40 mmHg)
- Elevate head of bed: 10–15 degrees (6–9 inch blocks) — reduces nocturnal supine HTN and nocturnal natriuresis; improves morning orthostatic tolerance
- Fluid and sodium intake: 2–3 L fluids/day; 6–10 g sodium/day (unless heart failure); rapid bolus of 500 mL water raises SBP within minutes
- Small, frequent meals: Reduces post-prandial hypotension (large meals cause splanchnic pooling)
- Avoid alcohol and hot environments: Vasodilation worsens OH; limit hot showers/baths
- Medication review: Reduce or eliminate antihypertensives, diuretics, alpha-blockers, and vasodilators when possible
Pharmacologic Treatment
| Medication | Mechanism | Dosing | Key Points |
|---|---|---|---|
| Midodrine | Alpha-1 adrenergic agonist — peripheral arterial and venous vasoconstriction | 2.5–10 mg TID; give upon waking, before lunch, and mid-afternoon (avoid after 4 PM) | First-line for nOH; onset 30–60 min, duration 2–4 hr; avoid supine position within 4 hours of dose; scalp tingling, piloerection, urinary retention |
| Droxidopa (Northera) | Norepinephrine prodrug — converted to NE by DOPA decarboxylase; restores deficient norepinephrine | 100–600 mg TID; titrate every 24–48 hours | FDA-approved specifically for nOH in synucleinopathies (PD, MSA, PAF); physiologic NE replacement; supine HTN risk; headache, dizziness; efficacy may wane over months |
| Fludrocortisone | Mineralocorticoid — sodium retention, plasma volume expansion, sensitizes alpha-adrenergic receptors | 0.05–0.2 mg daily (morning) | Adjunctive therapy; hypokalemia (supplement potassium), ankle edema, supine HTN (particularly problematic), heart failure exacerbation; caution in elderly |
| Pyridostigmine | Acetylcholinesterase inhibitor — enhances ganglionic neurotransmission and baroreflex gain | 30–60 mg TID | Modest BP elevation without worsening supine HTN (unique advantage); GI side effects; best as adjunctive agent |
| Atomoxetine | Norepinephrine reuptake inhibitor — potentiates residual noradrenergic tone | 10–18 mg BID | Effective in patients with residual sympathetic function (central lesions — MSA); not effective in complete postganglionic denervation (PAF); may worsen supine HTN |
| Caffeine | Adenosine antagonist — increases vascular resistance and reduces post-prandial hypotension | 100–200 mg with meals (1–2 cups of coffee) | Simple adjunctive measure; tolerance develops; best effect is blocking post-prandial BP drops |
| Erythropoietin | Stimulates red cell production — increases blood volume and viscosity; may also have direct vasoconstrictive effect | 25–50 IU/kg SC 3×/week | Reserved for refractory cases; requires monitoring of hematocrit; risk of polycythemia, hypertension |
Treatment Algorithm for Neurogenic OH
- Step 1: Non-pharmacologic measures (all patients) + medication review + elevate head of bed
- Step 2: Midodrine (first-line pharmacotherapy); add fludrocortisone if volume depletion suspected
- Step 3: Add droxidopa (especially in synucleinopathies) or substitute for midodrine
- Step 4: Combination therapy (midodrine + droxidopa + fludrocortisone); add pyridostigmine if supine HTN is limiting
- Step 5: Refractory cases — atomoxetine (if residual sympathetic function), erythropoietin, octreotide (for post-prandial hypotension)
- Throughout: Monitor and manage supine hypertension with elevating head of bed + short-acting bedtime antihypertensives
Disease-Specific Considerations
nOH in Parkinson Disease
- Prevalence: 30–50% of PD patients; increases with disease duration and severity
- Levodopa and dopamine agonists exacerbate OH through peripheral vasodilation
- Droxidopa is particularly appropriate (replaces deficient peripheral norepinephrine)
- Avoid abrupt changes in dopaminergic medication dosing — can precipitate severe OH
- Falls from nOH are a major cause of morbidity in PD; systematically screen at every visit
nOH in MSA
- Often the earliest and most severe autonomic feature; can precede motor symptoms by years
- Central mechanism — preganglionic sympathetic neuron loss; atomoxetine may be particularly effective (potentiates residual central NE)
- Supine hypertension is especially severe in MSA
- Prognosis is poor regardless of nOH treatment; mean survival 6–10 years from diagnosis
nOH in Diabetic Autonomic Neuropathy
- Most common peripheral cause of nOH; correlates with severity of somatic neuropathy
- Cardiovascular autonomic neuropathy (CAN) confers increased mortality risk
- Tight glycemic control may slow progression but rarely reverses established autonomic damage
- Midodrine is first-line; droxidopa also effective
Prognosis
The prognosis of nOH is primarily determined by the underlying etiology rather than the OH itself. However, nOH independently increases the risk of falls, syncope-related injuries, cardiovascular events, and mortality.
- MSA: Worst prognosis; progressive, median survival 6–10 years; nOH becomes increasingly refractory
- PD: nOH indicates more advanced disease and is associated with faster cognitive decline and increased mortality
- PAF: Relatively indolent course but risk of phenoconversion (14–34% over 5–10 years) to MSA, PD, or DLB
- Diabetic nOH: Associated with increased cardiovascular mortality; stabilization with glycemic control possible
- Autoimmune (AAG): Variable; may achieve remission with immunotherapy; chronic relapsing course in others
References
- Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567-1582.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13(8):875-891.
- Biaggioni I, Arthur Hewitt L, Engstrom SM, Figueroa JJ. Pressor effect of droxidopa in patients with neurogenic orthostatic hypotension: a pooled analysis of 3 randomized, placebo-controlled, phase 3 trials. Clin Auton Res. 2017;27(Suppl 1):S28.
- Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015;30(5):639-645.
- Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). Clin Auton Res. 2018;28(4):355-362.
- Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure: a meta-analysis. Neurology. 2018;90(15):e1386-e1391.
- Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7(5):451-458.
- Metzler M, Duerr S, Granata R, et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212-2219.
- Shibao CA, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013;7(4):317-324.
- Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015;66(7):848-860.